Key result
A 70-year-old woman with metastatic breast cancer developed possible chemotherapy-induced cardiomyopathy after receiving multiple lines of chemotherapy including mitoxantrone.
Case Report (n=1)
A case report detailing the history of a 70-year-old woman with metastatic breast cancer who developed possible chemotherapy-induced cardiomyopathy.
Answers are grounded in this paper and cite their sources.
May signal mitoxantrone cardiotoxicity risk in metastatic breast cancer; hypothesis-generating and should not change practice.
Case Study: H.M. is a 70-year-old woman with a known history of metastatic breast cancer. In 1995, she underwent a right modifi ed radical mastectomy followed by four years of hormonal therapy with tamoxifen. In April 2001, she was diagnosed with bone metastases and placed on letrozole, zoledronic acid, and chemotherapy consisting of gemcitabine and docetaxel. She experienced severe mucositis, and the chemotherapy was discontinued fi ve months later. In October 2001, she was started on 5-fl uorouracil, leucovorin, and mitoxantrone, which she continued until she was diagnosed with possible chemotherapy-induced cardiomyopathy in July 2003.
No takes yet. Share an insight, caveat, or question.
Burke et al. (2006) conducted a case report in Metastatic breast cancer and possible chemotherapy-induced cardiomyopathy (n=1). Chemotherapy (tamoxifen, letrozole, zoledronic acid, gemcitabine, docetaxel, 5-fluorouracil, leucovorin, mitoxantrone) was evaluated on Development of chemotherapy-induced cardiomyopathy. A 70-year-old woman with metastatic breast cancer developed possible chemotherapy-induced cardiomyopathy after receiving multiple lines of chemotherapy including mitoxantrone.
Synapse has enriched 10 related papers. Consider them for comparative context: